In prostate cancer, microbiota-informed NK cell biomarkers, such as upregulation of PD-1, TIM-3, increased CD56bright, and downregulated NKG2D, have been proposed to refine prognosis and guide clinical management strategies (109). The gene discussed is HAVCR2; the disease is prostate cancer.